Loading
Atigotatug is an experimental monoclonal antibody from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
Atigotatug (BMS-986489) is a monoclonal antibody developed by Bristol-Myers Squibb. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)), in non-small-cell lung cancer. The largest, NCT06646276, plans to enrol 530 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab.
1.Atigotatug binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Atigotatug" OR ABSTRACT:"Atigotatug" OR TITLE:"BMS-986489" OR ABSTRACT:"BMS-986489" OR TITLE:"BMS-986489 Atigotatug" OR ABSTRACT:"BMS-986489 Atigotatug") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Atigotatug, not a curated reading list.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.